2KobayashiS, Ide T,Sata M . Detection of YMDD motifmutations in some lain ivudine untrated asymptomatic hepatitis B virus carriers[J] . J Hepatol, 2001,34(4) : 584-586.
3Suzuki F,Tsubota A,Arase Y,etal Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hcpatitis B virus infcction in Japan[J]. Intervirology,2003 46(3) : 182-189.
2Atkins M, Hunt CM, Brown N, et al. Clinical signili- cance of YMDD mutant hepatitis B virus in a large co- hort of lamivudine- treated hepatitis B patients ( ab- stract) [J]. Hepatology, 1998,28 : 319A.
3Lok AS,Lai CL, Leung N,et al. Long- term safety of lamivudine treatment in patients with chronic hepa- titis B[J]. Gastroenterology. 2003,125 (6) : 1714 - 1722.
4Yeung P, Wong DK, Lai CL, et al. Association of hepatitis B virus pre- S deletions with the develop- ment of hepatoeellular carcinoma in chronic hepatitis B[J]. J Infect Dis,2011,203(5) :646 - 54.
5Schlaak JF, Tully G, Lohr HF, et al. HBV- specific immune defect in chronic hepatitis B is correlated with a dysregulation of pro- and anti - inflammatory cytokines[J]. Clin Exo Immunol, 1999,11 (5) : 508.
6Kobayashi S, Ide T, Sata M. Detetion of YMDD motif mutations in some lamivudine- untreated asympto matic hepatitis B virus carriers [J]. J Hepatology, 2001,34:584 - 586.
7Kessler HH, Pierer K,Santner BI,et al. Quantitative detection of hepatitis B virus DNA with a new PCR assay[J]. Clin Chem Lab Med,1998,36(8) :601 - 604.
8Neumaier M,Braun A,Wagener C. Fundamentals of quality assess- ment of molecular amplification meth ods in clinical diagnostics. International federation of clinical chemistry scientific division committee on mo- lecular biology techniques [J]. Clin Chem, 1998, 44 (1):11-26.
